MARKET

MYOK

MYOK

MyoKardia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

44.20
-2.68
-5.72%
Closed 16:06 04/01 EDT
OPEN
45.74
PREV CLOSE
46.88
HIGH
46.87
LOW
43.66
VOLUME
790.77K
TURNOVER
--
52 WEEK HIGH
78.28
52 WEEK LOW
43.50
MARKET CAP
2.06B
P/E (TTM)
-7.2496
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MYOK stock price target is 88.10 with a high estimate of 104.00 and a low estimate of 73.00.

EPS

MYOK News

More
  • MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients
  • GlobeNewswire · 2d ago
  • MyoKardia Reports Mavacamten Treatment Well Tolerated, Significantly Reduced Biomarkers Of Cardiac Injury, Wall Stress In Non-Obstructive Hypertrophic Cardiomyopathy Patients
  • Benzinga · 2d ago
  • The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty
  • Benzinga · 3d ago
  • Hedge Funds Were Buying MyoKardia, Inc. (MYOK) Before The Coronavirus
  • Insider Monkey · 5d ago

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About MYOK

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
More

Webull offers kinds of Myokardia Inc stock information, including NASDAQ:MYOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYOK stock news, and many more online research tools to help you make informed decisions.